SQZB
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q3 | -0.80 | $0 | -$15M |
| 2023 Q2 | -0.57 | $178,000 | -$15M |
| 2023 Q1 | -0.60 | $0 | -$24M |
| 2022 Q4 | -0.46 | $12M | -$21M |
| 2022 Q3 | -0.77 | $3M | -$22M |
| 2022 Q2 | -0.78 | $3M | -$21M |
| 2022 Q1 | -0.75 | $3M | -$21M |
| 2021 Q4 | -0.42 | $12M | -$21M |